News | Stents Bioresorbable | October 30, 2015

ABSORB China Trial Shows Bioresorbable Stent is Non-Inferior to DES

Absorb China among the late-breaking clinical data at TCT 2015

October 30, 2015 — Results from a clinical trial showed that that the Abbott Absorb everolimus-eluting bioresorbable vascular scaffold was non-inferior after one year compared to a current generation metallic drug-eluting stent (DES) in patients with coronary artery disease for the primary endpoint of angiographic in-segment late loss (LL). Findings from ABSORB China study were presented at the 2015 annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. 

ABSORB China was an angiographically based randomized trial designed to evaluate the relative effectiveness of bioresorbable vascular scaffolds (BVS) and cobalt-chromium everolimus-eluting stents (CoCr-EES); the trial was conducted for regulatory approval of BVS in China. 

A prospective, randomized, active-controlled, open-label, multicenter trial, ABSORB China randomized a total of 480 eligible patients with one or two de novo native coronary artery lesions in a 1:1 ratio at 24 sites in China. Patients were randomized to BVS (n=241) or CoCr-EES (n=239). The primary endpoint was angiographic in-segment late loss (LL), defined as the change in minimal lumen diameter from post-procedure to one year, and powered for non-inferiority with a margin of 0.15 mm.

The primary endpoint of in-segment LL at one year was 0.19 ± 0.38 mm for BVS (n=200) compared to 0.13 ± 0.38 mm for CoCr-EES (n=195); the one-sided 97.5% upper confidence limit of the difference was 0.14 mm, achieving non-inferiority of BVS compared to CoCr-EES (Pnon-inferiority=0.01). BVS and CoCr-EES also had similar one-year rates of target lesion failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization; 3.4% vs. 4.2% respectively, P=0.62) and definite/probable scaffold/stent thrombosis (0.4% vs. 0.0% respectively, p=1.0). 

“Results from ABSORB China show that BVS was non-inferior to CoCr-EES for the primary endpoint of in-segment late loss at one year,” said lead investigator Run-Lin Gao, M.D. He is professor of medicine and chief cardiologist at Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences in Beijing, China. “Similar one-year clinical safety and effectiveness outcomes were also observed. Additional studies are needed to assess BVS outcomes in complex patients and lesions encountered in daily practice, as well as long-term clinical outcomes data to assess the ultimate safety and efficacy profile of BVS compared to CoCr-EES.”

The ABSORB China trial was funded by Abbott Vascular. Gao reported receiving a research grant from Abbott Vascular.

For more information: www.crf.org 

Related Content

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials prese
TCT 2020 Late-breaking Study trial Presentations Announced. #TCTconnect #TCT2020 #TCT
Feature | TCT | October 29, 2020
October 29, 2020 — The late-breaking studies are one of the hallmarks of the annual...
Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

Interventional cardiology and structural heart pioneer Martin Leon, M.D., is the name-sake of the new joint ACC-CRF Center for Cardiovascular Transformation. 

News | TCT | October 14, 2020
October 14, 2020 — The American College of Cardiology (ACC) and the...
Videos | TCT | August 01, 2020
With COVID-19 forcing all medical conferences to go virtual in 2020,...
EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment for structural heart procedures. #TCT2019 #TCT #TCT19

EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment in structural heart procedures. (Photos by Dave Fornell)

Feature | TCT | November 04, 2019 | Dave Fornell, Editor
The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...
TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019
The Cardiovascular Research Foundation (CRF) has announced the 12 late-breaking trials and 16 late-breaking science...
Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the ex
cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.
Feature | TCT | September 21, 2018
October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clini
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics. #TCT #TCT18 #TCT2018
Feature | TCT | September 14, 2018 | Dave Fornell, Editor
The volume of information attendees receive at the annual...